1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   
   
3. Who will be able to view these files?
   Response - Anyone
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [ATHARVD517@GMAIL.COM].
   


6. For how long will this data be available start date provided 01-12-2025 and end date provided 31-07-2027?
   Response - Immediately following publication. No end date.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Androgenetic alopecia (AGA), commonly known as male pattern baldness, is one of the most prevalent forms of hair loss affecting a significant proportion of males, particularly those over the age of 30. This condition can have a profound impact on a person’s self-esteem, social interactions, and overall quality of life. Despite the availability of treatment options such as minoxidil and finasteride, these therapies have limitations in terms of efficacy, side effects, and long-term sustainability.

Microneedling, a procedure involving the use of small needles to create controlled micro-injuries to the scalp, has gained attention as an effective treatment for AGA by promoting hair regrowth through collagen induction and enhancing the absorption of topical treatments. It has shown promise in improving hair density, regrowth, and scalp health when used either alone or in combination with other therapeutic agents.

On the other hand, dutasteride, a 5-alpha-reductase inhibitor, has proven effectiveness in the treatment of AGA by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), a hormone responsible for hair follicle miniaturization in AGA. While dutasteride is primarily used in oral form, recent studies suggest that topical applications of dutasteride may provide the same benefits with reduced systemic side effects, making it an appealing option for localized treatment.

Despite promising individual results with Microneedling and Application of Topical dutasteride, there is limited research on their combined use for treating AGA. Combining microneedling with dutasteride could theoretically amplify the beneficial effects of both treatments by increasing the absorption of dutasteride through the micro-channels created during the microneedling process and enhancing the regenerative effects of the treatment. This combination approach may also mitigate the limitations of each individual therapy, offering a safer and more effective alternative for patients with moderate to severe AGA.